IVIg add-on versus standard of care for COVID-19 in adults with severely impaired B-cell function

Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Privigen plus standard of care with Standard of care alone (2 arms). Primary endpoint: Clinical recovery with plasma viral clearance at Day 28 without additional SARS-CoV-2-directed treatment. Planned start Feb 2026; status: authorised.